Getein Biotech Inc (603387) - Net Assets
Based on the latest financial reports, Getein Biotech Inc (603387) has net assets worth CN¥2.93 Billion CNY (≈ $429.21 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.70 Billion ≈ $541.26 Million USD) and total liabilities (CN¥765.68 Million ≈ $112.04 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 603387 goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.93 Billion |
| % of Total Assets | 79.3% |
| Annual Growth Rate | 38.71% |
| 5-Year Change | 25.74% |
| 10-Year Change | 733.73% |
| Growth Volatility | 63.23 |
Getein Biotech Inc - Net Assets Trend (2012–2025)
This chart illustrates how Getein Biotech Inc's net assets have evolved over time, based on quarterly financial data. See operational self-sufficiency of Getein Biotech Inc to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Getein Biotech Inc (2012–2025)
The table below shows the annual net assets of Getein Biotech Inc from 2012 to 2025. For live valuation and market cap data, see 603387 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.86 Billion ≈ $418.42 Million |
+5.09% |
| 2024-12-31 | CN¥2.72 Billion ≈ $398.16 Million |
-0.74% |
| 2023-12-31 | CN¥2.74 Billion ≈ $401.13 Million |
+2.88% |
| 2022-12-31 | CN¥2.66 Billion ≈ $389.91 Million |
+17.18% |
| 2021-12-31 | CN¥2.27 Billion ≈ $332.76 Million |
+13.47% |
| 2020-12-31 | CN¥2.00 Billion ≈ $293.25 Million |
+19.17% |
| 2019-12-31 | CN¥1.68 Billion ≈ $246.08 Million |
+21.58% |
| 2018-12-31 | CN¥1.38 Billion ≈ $202.40 Million |
+20.51% |
| 2017-12-31 | CN¥1.15 Billion ≈ $167.95 Million |
+234.65% |
| 2016-12-31 | CN¥342.96 Million ≈ $50.19 Million |
+27.68% |
| 2015-12-31 | CN¥268.60 Million ≈ $39.30 Million |
+62.60% |
| 2014-12-31 | CN¥165.19 Million ≈ $24.17 Million |
+96.51% |
| 2013-12-31 | CN¥84.06 Million ≈ $12.30 Million |
+106.91% |
| 2012-12-31 | CN¥40.63 Million ≈ $5.95 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Getein Biotech Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 14084.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.73 Billion | 62.96% |
| Other Components | CN¥1.02 Billion | 37.04% |
| Total Equity | CN¥2.75 Billion | 100.00% |
Getein Biotech Inc Competitors by Market Cap
The table below lists competitors of Getein Biotech Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Guangdong Eastone Century Technology Co Ltd
SHE:300310
|
$601.21 Million |
|
Beijing Scitop Bio Tech Co Ltd
SHE:300858
|
$601.50 Million |
|
Shenzhen Keanda Electronic Techno
SHE:002972
|
$601.90 Million |
|
Harbin Jiuzhou Electrical Co Ltd
SHE:300040
|
$602.57 Million |
|
Korea Investment Holdings Co Ltd
KO:071055
|
$600.87 Million |
|
CorMedix Inc
NASDAQ:CRMD
|
$600.87 Million |
|
Carriage Services Inc
NYSE:CSV
|
$600.84 Million |
|
Hunan Fangsheng Pharm Co Ltd
SHG:603998
|
$600.75 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Getein Biotech Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,618,960,854 to 2,752,734,720, a change of 133,773,866 (5.1%).
- Net income of 220,661,382 contributed positively to equity growth.
- Dividend payments of 103,237,250 reduced retained earnings.
- Other comprehensive income decreased equity by 280,963,968.
- Other factors increased equity by 297,313,701.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥220.66 Million | +8.02% |
| Dividends Paid | CN¥103.24 Million | -3.75% |
| Other Comprehensive Income | CN¥-280.96 Million | -10.21% |
| Other Changes | CN¥297.31 Million | +10.8% |
| Total Change | CN¥- | 5.11% |
Book Value vs Market Value Analysis
This analysis compares Getein Biotech Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.49x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 55.51x to 1.49x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | CN¥0.15 | CN¥8.10 | x |
| 2013-12-31 | CN¥0.31 | CN¥8.10 | x |
| 2014-12-31 | CN¥0.43 | CN¥8.10 | x |
| 2015-12-31 | CN¥0.70 | CN¥8.10 | x |
| 2016-12-31 | CN¥0.90 | CN¥8.10 | x |
| 2017-12-31 | CN¥2.64 | CN¥8.10 | x |
| 2018-12-31 | CN¥2.64 | CN¥8.10 | x |
| 2019-12-31 | CN¥3.17 | CN¥8.10 | x |
| 2020-12-31 | CN¥3.62 | CN¥8.10 | x |
| 2021-12-31 | CN¥4.12 | CN¥8.10 | x |
| 2022-12-31 | CN¥4.88 | CN¥8.10 | x |
| 2023-12-31 | CN¥5.03 | CN¥8.10 | x |
| 2024-12-31 | CN¥5.15 | CN¥8.10 | x |
| 2025-12-31 | CN¥5.43 | CN¥8.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Getein Biotech Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.02%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 20.98%
- • Asset Turnover: 0.28x
- • Equity Multiplier: 1.36x
- Recent ROE (8.02%) is below the historical average (28.54%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 55.48% | 29.82% | 0.82x | 2.27x | CN¥18.00 Million |
| 2013 | 78.07% | 42.56% | 1.00x | 1.84x | CN¥57.22 Million |
| 2014 | 46.37% | 35.73% | 1.02x | 1.27x | CN¥58.93 Million |
| 2015 | 39.43% | 38.01% | 0.84x | 1.23x | CN¥78.42 Million |
| 2016 | 40.68% | 37.49% | 0.85x | 1.28x | CN¥104.35 Million |
| 2017 | 16.96% | 39.70% | 0.39x | 1.11x | CN¥79.64 Million |
| 2018 | 18.55% | 36.37% | 0.44x | 1.17x | CN¥115.08 Million |
| 2019 | 20.90% | 35.08% | 0.48x | 1.24x | CN¥177.17 Million |
| 2020 | 16.58% | 27.13% | 0.42x | 1.47x | CN¥120.93 Million |
| 2021 | 18.94% | 28.46% | 0.45x | 1.49x | CN¥188.35 Million |
| 2022 | 20.10% | 27.38% | 0.50x | 1.48x | CN¥250.66 Million |
| 2023 | 10.93% | 20.43% | 0.36x | 1.47x | CN¥23.84 Million |
| 2024 | 8.54% | 19.20% | 0.31x | 1.42x | CN¥-38.26 Million |
| 2025 | 8.02% | 20.98% | 0.28x | 1.36x | CN¥-54.61 Million |
Industry Comparison
This section compares Getein Biotech Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $3,442,122,104
- Average return on equity (ROE) among peers: 12.05%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Getein Biotech Inc (603387) | CN¥2.93 Billion | 55.48% | 0.26x | $601.12 Million |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $4.98 Billion | -4.70% | 0.37x | $371.06 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $2.13 Billion | 17.09% | 0.37x | $3.63 Billion |
| Double Medical Technology Inc (002901) | $3.11 Billion | 2.98% | 0.27x | $2.56 Billion |
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | $6.77 Billion | 62.15% | 0.36x | $506.97 Million |
| Lepu Medical Tech Beijing (300003) | $10.54 Billion | 17.10% | 0.73x | $3.19 Billion |
| INKON Life Technology Co Ltd (300143) | $343.97 Million | 0.00% | 1.34x | $764.39 Million |
| Edan Instruments Inc (300206) | $1.25 Billion | 3.50% | 0.14x | $1.15 Billion |
| Guangdong Biolight Meditech Co Ltd (300246) | $1.39 Billion | -4.69% | 0.82x | $735.30 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $761.02 Million | 12.92% | 0.49x | $467.29 Million |
| Sinocare Inc (300298) | $3.14 Billion | 14.20% | 0.47x | $1.17 Billion |
About Getein Biotech Inc
Getein Biotech, Inc researches, develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. The company provides point-of-care detection, chemiluminescence detection, biochemical analysis, molecular testing, thrombus and hemostasis detection, blood cell analysis detection, urine analysis, quality control products, diagnostic raw materials, biochemical … Read more